DE COURCY LUCKETT: Open Payments
NPI 1023410578 · NATIONAL CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$714 in 28 payments from 12 companies in 2025. Trend: 2023 $733 · 2024 $135 · 2025 $714
Food & beverage: $714
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $174 |
| Otsuka America Pharmaceutical, Inc. | 3 | $161 |
| PFIZER INC. | 5 | $110 |
| Lilly USA, LLC | 3 | $68 |
| Exact Sciences Corporation | 2 | $42 |
| Indivior Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Novo Nordisk Inc | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
Products named: REXULTI, FARXIGA, AIRSUPRA, ELIQUIS, JARDIANCE, MOUNJARO, PREVNAR 20, SUBLOCADE.
Industry payments across CA — which companies pay providers there.
